SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Primary Objective:

Participants achieving an Objective Response Rate

Secondary Objective:

* Progression Free Survival
* Overall Survival
* Response Duration
* Safety
Diffuse Large B-cell Lymphoma
DRUG: SAR3419
Number of participants achieving an Objective Response Rate, 18 months
Number of participants with Adverse Events, Up to 1 year|Response duration - Time, Up to 18 months after the first infusion of the last patient|Progression Free Survival - Time, Up to 18 months after the first infusion of the last patient|Overall Survival - Time, Up to 18 months after the first infusion of the last patient
The screening period = up to 4 weeks prior to SAR3419 administration

The treatment period = from the day of first administration of SAR3419 until the End-Of-Treatment visit. All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity or other reasons for therapy discontinuation - After therapy discontinuation all patients will enter a safety follow-up period of 42 days starting from the day of administration of the last dose of SAR3419 and ending with the End Of Treatment visit.

All patients, regardless whether they have progressed or not, will be followed until death or end of study to evaluate survival for at least 18 months.